---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-062270"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2024-05-16T23:59:59+00:00"
generated_at: "2026-06-01T22:22:08.479001+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics receives conversion notice for 135,431 Series C Preferred shares into ~888K common shares

## Summary
- Holder converted 135,431 Series C Preferred shares into 888,072 common shares at $1.22 per share.
- Conversion increases outstanding common shares by approximately 888,000, diluting existing shareholders.
- Notice received May 13, 2024; conversion effective upon notice.

## SEC filing metadata
- accession: 0001104659-24-062270
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2024-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465924062270/0001104659-24-062270-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465924062270/tm2414630d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-062270
- JSON: https://secwatch.observer/filing/0001104659-24-062270.json
- Plain text: https://secwatch.observer/filing/0001104659-24-062270.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.